European Journal of Biomedical and Pharmaceutical Sciences

THE ANTICIPATED COVID-19 VACCINE WILL KEEP THE WORLD PHARMACOVIGILANCE SYSTEMS VERY BUSY

Mohammed G. Maslub* and Mahasen A. Radwan

ABSTRACT

Coronavirus Disease 2019 (COVID-19) pandemic demands the development of a suitable vaccine accordingly; pharmaceutical companies ubiquitously spare no effort to achieve the hopeful vaccine in the near future. The novel vaccine may possess risks of adverse drug reactions (ADRs) which may be over looked during the crushed time of development and testing. Therefore, this article discusses the problems which the partakers particularly, pediatric populations may suffer from the expected vaccine. This in turn puts a lot of pressure on the pharmacovigilance systems everywhere. Moreover, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is regarded as one of the RNA viruses that exhibit high extent of genetic mutations so that the anticipated vaccine may not keep its effectiveness along with theses mutations and it may need revaccination every year. Furthermore, future COVID-19 vaccine may confront general challenges like any new vaccine under progress such as the cost of the final product and its ability to provide appropriate protection. Therefore, continuous post-marketing surveillance globally should ensure the efficacy, safety and stability of any forthcoming vaccines.

Keywords: COVID-19, vaccine, ADRs, Pharmacovigilance.